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INTRODUCTION 
Tuberculosis (TB) is emerging as a major health concern 
day by day. TB is a communicable chronic bacterial 
infection and still a leading human killer worldwide1. 
Each year, approximately 2 million persons worldwide 
die and 9 million become infected1. TB has returned with 
a new face and the global scourge multidrug resistant TB 
(MDR-TB) is reaching epidemic proportions.1 The 
prevalence of TB is continuing to increase because of the 
increased number of patients infected with human 
immunodeficiency virus, bacterial resistance to 
medications, increased international travels and 
immigration from countries with high prevalence, and 
the growing numbers of homeless and drug abusers.2 
Mycobacteria grow 20-100 times slower than other 
bacteria and it take 4-6 weeks to obtain a colony for drug 
sensitivity studies. TB is treated with a multidrug 
regimen, and is thus exceptionally vulnerable to 
incidences of side effects, unsatisfactory patient 
compliances and slow improvement of patients.3 TB 
germs usually spread through air. When a patient with 
pulmonary TB coughs or sneezes, germs are spread in 
the air in the form of tiny droplets4 and such droplets 
when inhaled by a healthy person are then taken up by 
alveolar macrophages, initiating a cascade of events that 
result in either successful containment of the infection or 
progression to active disease (primary progressive TB).5 
The current treatments of tuberculosis are limited by 
their methods of delivery. Oral bioavailability of 
rifampicin (RIF) is 90-95%6 and the doses above those 
currently administered would present the risk of toxic 
side effects. Targeting anti-tubercular drugs such as RIF 
to the lung may increase the local therapeutic effect and 
reduce systemic exposure7. Pulmonary drug delivery 
system is gaining popularity as it is possible to achieve 
local and systemic delivery of drugs directly to lungs for 
the treatment of chronic obstructive pulmonary diseases 
and other respiratory diseases. Since last decade 
sustained release microspheres have been proposed for 
pulmonary delivery with major advantage of avoiding 
systemic toxicity by local delivery of the drug.8-9 Due to 
chronic oral systemic usage of presently available 
anti-tubercular agents produces patient non-
compliance and systemic side effects.10  The problems 
and issues surrounding the treatment of TB infections 
and disease are more complex because of body 
defense appears to have little effect on the bacteria and 
poor lung permeation of available drugs.11 Pulmonary 
delivery of drug has become an attractive target 
and of tremendous scientific and biomedical 
interest in the health care research area as the lung 
is capable of absorbing pharmaceuticals either for 
local deposition or for systemic delivery. 12 It is one 
of the most non-invasive approach of drug delivery to 
the lung by which unwanted systemic absorption of 
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drugs delivered for the local treatment of respiratory 
disease can be reduced.13-14 The high frequency of 
pulmonary tuberculosis demands the development of 
novel drug delivery approaches that enhances the 
bioavailability of the drug at the level of lungs.15  
Enhancement in solubility and permeation of poorly 
soluble drugs in cyclodextrin inclusion complex 
form has been reported. Cyclodextrins act as 
permeation enhancers by carrying the drug through the 
aqueous barriers which exists before the lipophilic 
surface of biological membranes.16 Sugars and 
cyclodextrins though compatible with lung can 
cause bronchoconstriction in many of the 
hypersensitive individuals12. Olibanum resin 
forms an excellent coat material in the resin coated 
microcapsules and exhibited good controlled release 
characteristics. Hence, the resin can be utilized as a 
matrix forming substance in the formulation of matrix 
tablets and film forming coating polymer for designing 
the microcapsules which can facilitate to attain once a 
day oral controlled release products.17 The 
Hydroxypropyl-β-cyclodextrin (HPβCD) with 
Olibanum gum resin containing RIF may be 
delivered to lungs by pulmonary route to improve 
the solubility and permeation of drug to achieve 
better treatment of TB. The lung comtatibilty and safty 
aspects of olibanub gum resin a natural polymer is yet to 
established. Hence present study was aimed to design 
microspheres of RIF with HPβCD by using extracted 
olibanum gum resin by a novel  spray-drying technique 
for improved therapeutic effect of poorly soluble 
RIF for lung delivery. 
MATERIALS AND METHODS 
RIF was obtained as generous gift sample from Lupin 
Pharmaceuticals, Mumbai, India. Olibanum Gum was 
purchased from Girijan Co-operative Ltd., 
Vishakhapattanum, Andhra Pradesh. HPβCD was 
obtained as gift sample from Gangwal chemicals, 
Mumbai, India. All other chemicals used were of 
analytical grade and were used without further 
purification. 
Extraction of resin fraction from Olibanum gum 
The resin present in powdered Olibanum gum (10 gm) 
was extracted repeatedly with 4×50 ml quantities of 
solvent ether. The ether extracts were collected in a 
porcelain dish and concentrated to dryness at 40º to 
obtain the resin fraction. The dry mass was powdered 
and the size was reduced to 200 mesh, packed in 
aluminium foil and stored in a deccicator till further 
use.17 
Preparation of spray-dried microspheres
18
 
Olibanum gum resin and RIF were dissolved one after 
another in 475 ml of Isopropyl alcohol with continuous 
stirring to get a clear homogeneous solution. HPβCD was 
dissolved in another beaker containing 25 ml distilled 
water to get a clear homogeneous solution. Solution of 
HPβCD was added slowly to resin and RIF solution and 
mixed together on a magnetic stirrer until a 
homogeneous solution was formed. Final solution thus 
formed was spray-dried using a mini spray-dryer (Lab-
Ultima-222, Mumbai) at the following predetermined 
conditions; nozzle diameter-0.7 mm, atomization 
pressure-1.5 kg/cm2, feed rate 5 ml/min, aspirator-45 %, 
inlet temperature- 70º  and outlet temperature 40º. The 
details of various formulation compositions are presented 
in Table 1. 
 
Table 1:  Formulation details of RIF loaded pulmospheres 
 
Evaluation and Characterization of Spray dried 
microspheres  
Drug content
19
 
Known amount of crushed pulmospheres equivalent to 
50 mg of RIF were added to 10 ml of methanol in a 
centrifuge tube, kept overnight at 37º for complete 
swelling and extraction of drug. The content was 
centrifuged to remove polymeric debris. The clear 
supernatant solution was diluted suitably with phosphate 
buffer of pH 5.2 and pH 7.4 separately and analysed for 
drug content using UV-Visible spectrophotometer (Lab 
India 3200) at 475 nm. 
Particle Size analysis 
Particle Size Analysis was performed using Beckman 
Coulter, Delsa Nano (common) India. The particles of 
optimized formulation F1 and spray-dried pure RIF were 
dispersed separately in water and the mean particle size 
was determined. 
In- vitro dissolution studies
20-21
 
Spray-dried pulmospheres equivalent to 50 mg of drug 
were dispersed in 50 ml of dissolution media (7.4 
physiologic pH and 5.2 endosomal of alveolar 
macrophages pH) separately. The dissolution study was 
performed both in simulated normal physiological 
medium and simulated lung fluid to compare the drug 
release pattern in both the media. The test tubes were 
maintained at 370 in a horizontal-shaking bath and 
shaken at a rate of 90 cycles/min. At predetermined 
intervals, 1ml of the sample was withdrawn and filtered. 
The medium was replaced with fresh buffer solutions to 
maintain the total volume throughout the study. 200 
μg/ml ascorbic acid was added as an antioxidant to 
prevent oxidative degradation. The concentration of 
Batch code RIF Olibanum Resin HPβCD Isopropyl Alcohol 
F1 5gm 400mg 5gm 500ml 
F2 5gm 800 mg 2.5 gm 500ml 
F3 5gm 1200 mg 1.25 gm 500ml 
F4 5gm 800 mg - 500ml 
F5 - 800 mg 2.5 gm 500ml 
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rifampicin was determined by UV spectrophotometer at 
475 nm. 
Differential Scanning Calorimetry (DSC) 
DSC was performed on DSC D60 Shimadzu, Japan. 
About 5 mg of samples was sealed in aluminium pans 
and heated at the rate of 100/min. Covering temperature 
range was between 40-3000 under nitrogen atmosphere 
with a flow rate of 100 ml /min.  
Scanning Electron Microscopy (SEM)
22
 
The surface morphology of the samples was investigated 
using scanning electron microscope (Jeol, JSM-6360, 
Germany). SEM studies help to observe changes that 
occur in crystal structure during or after preparation. The 
samples were mounted onto stubs with double sided 
adhesive tape and sputter coated with coated with gold 
using a gold coater the instrument. The coated sample 
was observed under SEM instrument at the required 
magnification at room temperature. 
RESULTS AND DISCUSSION 
Percentage yield, Drug content and Particle size 
The results of percentage yield, drug content and mean 
particle size of spray-dried pulmospheres are mentioned 
in table 2. Percentage yield of all the formulations was 
found to be in the range of 48-50. No significant 
difference in the percentage yield of all the formulations 
was found. The drug content of all spray dried 
pulmospheres in both pH 5.2 and in pH 7.4 was found to 
be in the range of 98%-100%. The drug content was 
found to 100 % in case of SDPD whereas it was found to 
be 99 % for F1 and F2. There was no significant 
difference in drug content was found between all the 
formulations. Mean particle size of spray-dried pure drug 
(SDPD) and Formulation F1 was found to be 3.5 µm 
which was similar in both the cases and spray-dried 
particles were in the respirable size range suitable to 
administer through pulmonary route. The intensity 
distribution curves are shown in Figure 6 and 7. 
 
Table 2: Preliminary evaluation data of RIF loaded pulmospheres 
Batch Code Percentage Yield Drug content Mean Particle Size(µm) 
In pH 5.2 In pH 7.4  
SDPD 50% 100% ± 0.60 100%  ± 0.40 3.5 
F1 50% 99% ± 0.20 99% ± 0.90 3.5 
F2 48% 99% ± 0.90 99% ± 0.50 --- 
F3 49% 98% ± 0.40 98% ± 0.60 --- 
F4 48% 98% ± 0.70 99% ± 0.20 --- 
 
In Vitro drug release  
In-vitro dissolution study was carried by modified 
dissolution apparatus (rotator shaker method). The 
release profiles are shown in Figure 1 and 2. The drug 
release study was carried in both pH 5.2 and in pH 7.4 
for up to 72 h. The drug release from formulation F1 was 
highest in both the pH due to the presence of HPβCD. As 
the amount of HPβCD increased, solubility of RIF was 
also increased proportionally. Hence, the drug release 
was also found to be high. The cumulative release of RIF 
significantly decreased with increasing polymer 
concentration. The dissolution profile of drug from 
formulation containing olibanum resin in presence of 
HPβCD was improved as compared to pure drug. 
However, dissolution was greater in physiological media 
as compared to lung media in all the cases. The drug 
release from the formulation containing resin as a rate 
retarding material in presence of HPβCD has sown 
enormous improvement when compared to pure drug 
alone which has shown only 28% release. There was 3 
fold increases in dissolution rate found in pH 5.2 media. 
The drug release from SDPD was more as compared to 
pure drug in both dissolution media. 
  
 
Figure 1: In Vitro dissolution profile of F1, F2, F3, F4, SDPD and PD in pH 5.2 
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Figure 2: In Vitro dissolution profile of F1, F2, F3, F4, SDPD and PD in pH 7.4  
Characterisation of spray dried microspheres 
 Differential Scanning Calorimetry (DSC) 
DSC thermograms of pure RIF and optimized 
formulation F1 are shown in figures 3 and 4 respectively. 
The DSC thermogram of pure rifampicin has shown 
endothermic peak at 1980 which is due to melting of 
drug. The thermogram of F1 has shown broad 
endothermic peak near the melting point of drug that 
indictes the complete encapsulation of drug into the 
polymer matrix without degradation. 
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Figure 3: DSC Thermograms of pure Rifampicin 
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Figure 4: DSC Thermogram of formulation F1 
0
20
40
60
80
100
0 20 40 60 80
C
u
m
 %
 D
R
Time (hr)
In Vitro dissolution study of F1,F2,F3,F4,SDPD and PD in pH 7.4 
F1
F2
F3
F4
SDPD
PD
Patil et al                 JDDT; Special Issue1: "Drug Delivery using Nanomedicine & Nanotechnology"                19 
© 2011-14, JDDT. All Rights Reserved                                                ISSN: 2250-1177                                                CODEN (USA): JDDTAO 
Scanning Electron Microscopy (SEM) 
The SEM of pure RIF, Spray-dried pure RIF, optimized 
formulation F1 and HPβCD were shown in figure 5. The 
SEM study revealed that, pure drug has shown more 
crystalline nature of its typical and regular size, whereas, 
spray dried pure drug has shown lesser crystals and there 
was a formation of spherical drug particles having 
porous morphology. The formulation F1 shows smooth 
surface having folding and curves over it indicating the 
formation of perfect inclusion complex with HPβCD and 
complete encapsulation of drug in polymers matrix.  
 
              
    
               
Figure 5:  SEM microphotographs of pure Rifampicin (A), Spray dried pure Rifampicin (B), Formulation F1(C) 
and HPβCD (D) 
CONCLUSION 
This study reports for the first time the effect of 
cyclodextrin as a solubility enhancer in the sustained 
release rifampicin loaded pulmosphere formulation 
designed using naturally available, biocompatible 
olibanaum gum resin pulmosphere as a tare retarding 
polymer in order to improve its bioavailability for 
effective tuberculosis control. The developed 
pulmospheres demonstrated approximately 3 fold 
increased drug release compared with pure drug alone. 
The presence of cyclodextrin helped to achieve higher 
solubility and dissolution of rifampicin and olibanum 
gum resin was found to be a suitable rate retarding 
polymer to achieve desired sustained release of drug.  
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